Key facts
- · Type: Amendment first sale 2023-04-24 · Amount sold: $14.99M · Total offering: $15M · SEC filing
- · Type: Amendment first sale 2023-04-24 · Amount sold: $10.02M · Total offering: $12M · SEC filing
- · Type: Amendment first sale 2023-04-24 · Amount sold: $6.91M · Total offering: $8M · SEC filing
- · Type: New offering first sale 2023-04-24 · Amount sold: $187K · Total offering: $2.65M · SEC filing
LOWELL, MASSACHUSETTS
Other Health Care
4
$187K
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-10-02 | Amendment first sale 2023-04-24 | $14.99M | $15M | details · SEC filing |
| 2025-07-10 | Amendment first sale 2023-04-24 | $10.02M | $12M | SEC filing |
| 2024-07-10 | Amendment first sale 2023-04-24 | $6.91M | $8M | SEC filing |
| 2023-05-18 | New offering first sale 2023-04-24 | $187K | $2.65M | SEC filing |
Watch REVBIO, INC.
Get an email when REVBIO, INC. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with REVBIO, INC.?
Who to contact
- Brian Hess — Executive Officer, Director
- George Kay — Director
- D. Allen — Executive Officer, Director
- Kevin Foley — Director
- Round: Form D/A (amended) filed 2026-10-02
- Amount sold: $14.99M
- Industry: Other Health Care
- Based: LOWELL, MASSACHUSETTS
People listed
- Brian Hess — Executive Officer, Director
- George Kay — Director
- D. Allen — Executive Officer, Director
- Kevin Foley — Director
- Filing: Form D/A (amended) filed 2026-10-02
- Amount sold: $14.99M
- Industry group: Other Health Care
- Based: LOWELL, MASSACHUSETTS
- Entity type: Corporation
We'll show it in your MentionFox inbox when REVBIO, INC. raises, hires or launches. No email unless you switch it on.
Watch REVBIO, INC. →Want the whole picture on REVBIO, INC.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on REVBIO, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on REVBIO, INC. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from REVBIO, INC.'s own filings with the SEC. The people those filings name are on the team page.